Edition:
United States

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

59.80EUR
11:35am EST
Change (% chg)

€-0.70 (-1.16%)
Prev Close
€60.50
Open
€60.48
Day's High
€60.72
Day's Low
€59.70
Volume
23,463
Avg. Vol
49,280
52-wk High
€72.74
52-wk Low
€50.13

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros
Wednesday, 25 Oct 2017 01:01am EDT 

Oct 25 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO.9 MONTHS EBITDA EUR ‍​216.2 MILLION VERSUS EUR 214.1 MILLION YEAR AGO.9 MONTHS NET PROFIT EUR 132.1‍​ MILLION VERSUS EUR 131.3 MILLION YEAR AGO.‍FULL-YEAR 2017 GUIDANCE ADJUSTED, MID-TERM OUTLOOK CONFIRMED​.‍FOR 2017 NOW EXPECTS THAT SALES REVENUE GROWTH WILL REACH APPROX. 4% IN CONSTANT CURRENCIES ​.‍FOR 2017 UNDERLYING EBITDA MARGIN WILL BE APPROX. AT PRIOR-YEAR LEVEL OF 27.5%​.FOR 2017 ‍CAPITAL EXPENDITURES ARE EXPECTED TO BE AT UPPER END OF BANDWIDTH OF AROUND 10% TO 13% OF SALES.​.  Full Article

Sartorius Stedim Biotech cuts 2017 outlook
Tuesday, 17 Oct 2017 04:06am EDT 

Oct 17 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::REPORTED ON MONDAY 9-MONTH SALES REVENUE EUR 806 MLN, UP 3.3 PCT IN CONSTANT CURRENCIES.9-MONTH UNDERLYING EBITDA MARGIN AT 26.8 PCT VS 27.3 PCT YEAR AGO.IN 2017 SEES INCREASE OF SALES REVENUE IN CONSTANT CURRENCIES BY ABOUT 4 PCT (VS PREVIOUS GUIDANCE FROM ABOUT 8 PCT TO 12 PCT) .IN 2017 SEES UNDERLYING EBITDA MARGIN IN CONSTANT CURRENCIES AT ABOUT THE PRIOR-YEAR LEVEL OF 27.5 PCT (VS PREVIOUS GUIDANCE ABOUT +0.5 PCT POINTS VS FY 2016).CONFIRMS MID-TERM TARGETS.  Full Article

Sartorius Stedim Biotech 2017 first-half figures
Friday, 21 Jul 2017 01:01am EDT 

July 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH S.A.: 2017 FIRST-HALF FIGURES.H1 SALES EUR 546.7 MILLION VERSUS EUR 508.8 MILLION YEAR AGO.H1 EBITDA EUR 2) 147.4 MILLION VERSUS EUR 136.4 MILLION YEAR AGO.H1 NET PROFIT EUR 89.7 MILLION VERSUS EUR 83.5 MILLION YEAR AGO.SSB CONTINUES TO PROJECT CAPITAL EXPENDITURES OF AROUND 10% TO 13% OF SALES IN CURRENT YEAR..CONFIRMED ITS FULL-YEAR FORECAST FOR 2017.PROJECTS SALES REVENUE TO INCREASE BY ABOUT 8% TO 12%.PROJECTS UNDERLYING EBITDA MARGIN TO RISE BY APPROX. 0.5 PERCENTAGE POINTS OVER PRIOR-YEAR FIGURE OF 27.5%.BOTH FORECASTS GIVEN IN CONSTANT CURRENCIES.  Full Article

Sartorius Stedim Biotech, PACA region and Aix-Marseille Provence Metropolis launch 23 million euros R & D program
Wednesday, 29 Mar 2017 12:47pm EDT 

Sartorius Stedim Biotech Sa : Provence-Alpes-Côte d'Azur region, Aix-Marseille Provence Metropolis and co launch 23 million euros R & D program in Aubagne . Creation of 200 new jobs by the end of 2018 .Sees widening production capacity by one-third and doubling the size of the logistics platform.  Full Article

Sartorius Stedim Biotech proposes to increase dividend by 26 pct
Tuesday, 21 Feb 2017 09:29am EST 

Sartorius Stedim Biotech SA :Proposal to annual general shareholders` meeting to increase dividend by 26.0 pct to 0.42 euro ($0.4425) per share.  Full Article

Sartorius Stedim Biotech H1 revenue up 20.6 pct to 508.8 million euros
Monday, 25 Jul 2016 12:59am EDT 

Sartorius Stedim Biotech SA : H1 revenue 508.8 million euros ($558.41 million) versus 422.0 million euros year ago . H1 net profit 83.5 million euros versus 62.9 million euros year ago . H1 EBITDA 136.4 million euros versus 106.5 million euros year ago . Outlook for 2016 raised . Sales revenues are now expected to increase by about 17 pct to 20 pct in constant currencies .Underlying EBITDA margin is projected to rise about 1.5 percentage points in constant currencies.  Full Article

Sartorius Stedim Biotech Acquires U.S. start up Ksep systems
Wednesday, 6 Jul 2016 03:00am EDT 

Sartorius Stedim Biotech : Acquires U.S. start up Ksep systems . Transaction values Ksep at around $28 million and will be closed by end of July 2016 .Ksep holdings, inc. Expected to achieve significant double-digit growth and to generate around $7 million sales revenues and a strong double-digit EBITDA margin in 2016.  Full Article

Sartorius Stedim Biotech proposes FY 2015 dividend
Wednesday, 24 Feb 2016 07:00pm EST 

Sartorius Stedim Biotech SA:To submit proposal to pay a dividend of 2.00 euros per share for FY 2015, up from 1.30 euros a year earlier.  Full Article

Sartorius Stedim Biotech gives guidance for 2016 and 2020
Monday, 1 Feb 2016 01:00am EST 

Sartorius Stedim Biotech SA:Forecasts 2016 sales revenue will increase 12 pct to 16 pct and underlying EBITDA margin will rise approx. one percentage point​.‍Management anticipates that in 2020 sales revenue will reach about 1.5 to 1.6 billion euros and underlying EBITDA margin will attain about 29 to 30 pct.  Full Article

BRIEF-Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros

* 9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO